Biblio
The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote Reprogramming. Cell Rep. 2020;32(2):107877.
Self-Folding 3D Silk Biomaterial Rolls to Facilitate Axon and Bone Regeneration. Adv Healthc Mater. 2020:e2000530.
. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria. Acta Haematol. 2024.
. Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis. Cell Rep. 2023;42(3):112164.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994-1008.
Oral administration of hydroxylated-graphene quantum dots induces intestinal injury accompanying the loss of intestinal stem cells and proliferative progenitor cells. Nanotoxicology. 2019:1-13.
. Nasal Mucosa Derived-Mesenchymal Stem Cells from Mice Reduce Inflammation via Modulating Immune Responses. PLoS One. 2015;10(3):e0118849.
. MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. J Transl Med. 2018;16(1):267.
Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment. Cell Death Dis. 2023;14(8):525.
The memory effect of micro/nano-structures activating osteogenic differentiation of BMSCs. J Mater Chem B. 2023.
. ID1 expressing macrophages support cancer cell stemness and limit CD8 T cell infiltration in colorectal cancer. Nat Commun. 2023;14(1):7661.
hUC-MSC transplantation therapy effects on lupus-prone MRL/lpr mice at early disease stages. Stem Cell Res Ther. 2023;14(1):211.
Highly-expressed micoRNA-21 in adipose derived stem cell exosomes can enhance the migration and proliferation of the HaCaT cells by increasing the MMP-9 expression through the PI3K/AKT pathway. Arch Biochem Biophys. 2020:108259.
. EphA2-to-YAP Pathway Drives Gastric Cancer Growth and Therapy Resistance. Int J Cancer. 2019.
. Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone. Chronic Dis Transl Med. 2024;10(1):62-68.
. . .